Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis· 2006 · 68 citations
2. Management of Hyperglycemia in Type 2 Diabetes· 2012 · 524 citations
3. <i>Standards of Medical Care in Diabetes—2022</i> Abridged for Primary Care Providers· 2021 · 656 citations
4. Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world retrospective administrative database analysis in Japan· 2022 · 10 citations
5. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study· 2021 · 30 citations